Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05095701 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Immunity Persistence Study of Live Attenuated Varicella Vaccine

StatusEnrolling by Invitation
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study completion date: Dec 1, 2024 to Oct 1, 2025v4
  2. Study completion date: Jul 1, 2024 to Dec 1, 2024v3
  3. Trial status: Not Yet Recruiting to Enrolling by Invitationv2 Show 4 more changesShow less
    • Primary completion date changed from estimate of Dec 1, 2021 to Dec 19, 2021
    • Study completion date: Jul 1, 2022 to Jul 1, 2024
    • Start date changed from estimate of Nov 1, 2021 to Dec 18, 2021
    • Site contacts updated at 2 of 2 sites
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This an open phase Ⅳ clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunity persistence of live attenuated varicella vaccine at 5 and 8 years after primary immunization with live attenuated varicella vaccine.
Trial Details
NCT Number NCT05095701
Lead Sponsor Sinovac (Dalian) Vaccine Technology Co., Ltd.
Conditions
(from sponsor)		 Varicella
Related terms Chickenpox
Enrollment 703 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov